|
US6900226B2
(en)
*
|
2000-09-06 |
2005-05-31 |
Hoffman-La Roche Inc. |
Neuropeptide Y antagonists
|
|
CA2468015A1
(en)
*
|
2001-11-27 |
2003-06-05 |
Merck & Co., Inc. |
2-aminoquinoline compounds
|
|
JP4216196B2
(ja)
*
|
2002-02-04 |
2009-01-28 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｎｐｙアンタゴニストとしてのキノリン誘導体
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
EP1560816A1
(en)
|
2002-07-05 |
2005-08-10 |
F. Hoffmann-La Roche Ag |
Quinazoline derivatives
|
|
AU2003253364B2
(en)
|
2002-08-07 |
2007-06-07 |
F. Hoffmann-La Roche Ag |
Thiazole derivatives
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
CA2518398A1
(en)
*
|
2003-03-10 |
2004-09-23 |
Schering Corporation |
Heterocyclic kinase inhibitors: methods of use and synthesis
|
|
JP4765627B2
(ja)
|
2003-09-22 |
2011-09-07 |
Ｍｓｄ株式会社 |
新規ピペリジン誘導体
|
|
EP1687002A4
(en)
|
2003-11-10 |
2008-07-23 |
Synta Pharmaceuticals Corp |
CONDENSED HETEROCYCLIC COMPOUNDS
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
US20060183763A1
(en)
*
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
|
CA2618112A1
(en)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
Pyridone compound
|
|
WO2007024004A1
(ja)
|
2005-08-24 |
2007-03-01 |
Banyu Pharmaceutical Co., Ltd. |
フェニルピリドン誘導体
|
|
AU2006288153A1
(en)
|
2005-09-07 |
2007-03-15 |
Msd K.K. |
Bicyclic aromatic substituted pyridone derivative
|
|
CA2627139A1
(en)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
Novel benzoxathiin derivative
|
|
ES2381205T3
(es)
|
2005-11-10 |
2012-05-24 |
Msd K.K. |
Derivado espiro aza-sustituido
|
|
WO2008020302A2
(en)
*
|
2006-08-17 |
2008-02-21 |
Pfizer Products Inc. |
Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
|
|
WO2008047544A1
(en)
|
2006-09-28 |
2008-04-24 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Ｍｓｄ株式会社 |
インドールジオン誘導体
|
|
WO2008141077A1
(en)
*
|
2007-05-10 |
2008-11-20 |
Janssen Pharmaceutica N.V. |
Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
|
|
WO2008142384A1
(en)
|
2007-05-17 |
2008-11-27 |
Helperby Therapeutics Limited |
Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
|
|
US20080303428A1
(en)
*
|
2007-06-01 |
2008-12-11 |
Vsevolod Rostovtsev |
Chrysenes for green luminescent applications
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX2009013293A
(es)
|
2007-06-04 |
2010-02-15 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
|
|
HRP20120328T2
(hr)
*
|
2007-11-15 |
2012-09-30 |
Gilead Sciences |
Inhibitori replikacije virusa humane imunodeficijencije
|
|
WO2009062285A1
(en)
|
2007-11-16 |
2009-05-22 |
Boehringer Ingelheim International Gmbh |
Inhibitors of human immunodeficiency virus replication
|
|
JPWO2009110510A1
(ja)
|
2008-03-06 |
2011-07-14 |
Ｍｓｄ株式会社 |
アルキルアミノピリジン誘導体
|
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
JPWO2009154132A1
(ja)
|
2008-06-19 |
2011-12-01 |
Ｍｓｄ株式会社 |
スピロジアミン−ジアリールケトオキシム誘導体
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
JPWO2010013595A1
(ja)
|
2008-07-30 |
2012-01-12 |
Ｍｓｄ株式会社 |
５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
MX348131B
(es)
|
2011-02-25 |
2017-05-26 |
Merck Sharp & Dohme |
Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
|
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2014130608A1
(en)
|
2013-02-22 |
2014-08-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
|
EA201592263A1
(ru)
|
2013-06-05 |
2016-05-31 |
Синерджи Фармасьютикалз, Инк. |
Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
EP3558298B1
(en)
|
2016-12-20 |
2026-03-11 |
Merck Sharp & Dohme LLC |
Antidiabetic spirochroman compounds
|
|
US11344543B2
(en)
*
|
2017-07-14 |
2022-05-31 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|